Development of Antimicrobial Peptides as Topical Microbicides

抗菌肽作为局部杀菌剂的开发

基本信息

  • 批准号:
    8092553
  • 负责人:
  • 金额:
    $ 19.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

We hypothesize that novel anti-HIV and anti-STI topical microbicides based on natural antimicrobial peptides collected in the Antimicrobial Peptide Database developed by the co-PI's laboratory (http://aps.unmc.due/AP/main.html) can be discovered and improved through peptide engineering technology. During the R21 phase, we will methodically screen peptides from the database and define specific inhibitors of HIV and HSV-2 as well as broad based inhibitory peptides. These active agents will be further developed in order to understand their range and mechanism of anti-HIV action. Superior peptides identified in SA1 will be characterized in SA2 to provide a rationale for continued development in SA3 using various molecular strategies which will result in the improvement of the therapeutic index of the peptide agents, with and without other small molecule microbicides, in order to begin development of an effective microbicide product. This product will be formulated and evaluated in animal models and safety assessment studies in the R33 portion of the project. Our goal is to produce a female controlled preventative agent which can be utilized to prevent the sexual transmission of viral, bacterial and fungal organisms with a focus on inhibiting the transmission of HIV. The research data will be entered into the existing antimicrobial peptide database to facilitate the use by funding agencies, other researchers, students and the public.
我们假设,基于co-PI实验室开发的抗菌肽数据库(http://aps.unmc.due/AP/main.html)中收集的天然抗菌肽,可以通过肽工程技术发现并改进新型抗hiv和抗sti局部杀微生物剂。在R21阶段,我们将有系统地从数据库中筛选肽,并确定HIV和HSV-2的特异性抑制剂以及广泛的抑制肽。这些活性药物将进一步开发,以了解其抗hiv作用的范围和机制。在SA1中鉴定的优质肽将在SA2中进行表征,为SA3的持续开发提供理论依据,使用各种分子策略将导致肽剂治疗指数的提高,无论是否使用其他小分子杀微生物剂,以便开始开发有效的杀微生物剂产品。该产品将在项目R33部分的动物模型和安全性评估研究中进行配方和评估。我们的目标是生产一种女性控制的预防剂,可用于防止病毒、细菌和真菌生物体的性传播,重点是抑制艾滋病毒的传播。研究数据将输入现有的抗菌肽数据库,以方便资助机构、其他研究人员、学生和公众使用。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Post-translational Modifications of Natural Antimicrobial Peptides and Strategies for Peptide Engineering.
  • DOI:
    10.2174/2211550111201010072
  • 发表时间:
    2012-02
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wang G
  • 通讯作者:
    Wang G
Natural antimicrobial peptides as promising anti-HIV candidates.
天然抗菌肽作为有前景的抗艾滋病候选药物。
Database-Guided Discovery of Potent Peptides to Combat HIV-1 or Superbugs.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Walter Buckheit其他文献

Robert Walter Buckheit的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Walter Buckheit', 18)}}的其他基金

Critical Path IND-enabling Studies, Regulatory, and Product Development
关键路径 IND 支持研究、监管和产品开发
  • 批准号:
    8405106
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Determination of Dosing Concentrations of Formulated APIs using the MTSA
使用 MTSA 确定配方 API 的剂量浓度
  • 批准号:
    8404125
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
  • 批准号:
    8699496
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
  • 批准号:
    8862358
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Administrative
行政的
  • 批准号:
    8405107
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
  • 批准号:
    8374028
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
  • 批准号:
    8494567
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Development and Evaluation of Dual Compartment Combination Microbicides
双室组合杀菌剂的开发与评价
  • 批准号:
    9060880
  • 财政年份:
    2012
  • 资助金额:
    $ 19.51万
  • 项目类别:
Advanced Preclinical and Clinical Development and Regulatory Evaluations
先进的临床前和临床开发以及监管评估
  • 批准号:
    8132428
  • 财政年份:
    2010
  • 资助金额:
    $ 19.51万
  • 项目类别:
Discovery of drugs for use in the treatment and prevention of HIV infection using
发现用于治疗和预防 HIV 感染的药物
  • 批准号:
    7932473
  • 财政年份:
    2010
  • 资助金额:
    $ 19.51万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 19.51万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 19.51万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 19.51万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 19.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 19.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 19.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 19.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 19.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 19.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了